Key result
LEVO-D score predicts hospitalization in advanced heart failure with an AUC of ~0.81.
Why the study?
Does the LEVO-D score predict hospitalisation, clinical response, and mortality in patients with advanced heart failure receiving intermittent levosimendan infusions?
Observational (n=67)
No
Does the LEVO-D score predict hospitalisation, clinical response, and mortality in patients with advanced heart failure receiving intermittent levosimendan infusions?
The LEVO-D score is a useful tool for predicting hospitalization in advanced heart failure patients receiving intermittent levosimendan infusions, though its ability to predict mortality is poor.
Answers are grounded in this paper and cite their sources.
Supports LEVO-D adoption for advanced HF prognostication; extends validation to real-world cohorts with high OMT and low TEER.
BACKGROUND: Advanced heart failure is a prevalent and burdensome condition, and effective therapies are needed. Ambulatory intermittent levosimendan infusion has been used to reduce cardiovascular events, although response rates vary. This study assessed the LEVO-D score as a predictive tool in patients receiving levosimendan infusions under standardised conditions. METHODS: We conducted a prospective observational study at the Heart Failure Clinic of a tertiary-level teaching hospital between September 2020 and March 2024. A total of 67 patients received a median of 10 intermittent levosimendan infusions and were followed for a mean duration of 18 months. The performance of the LEVO-D score was assessed using receiver operating characteristic (ROC) curve analysis and descriptive statistics. RESULTS: The patients were elderly, with a mean age of 69.5 years, a high comorbidity burden, and an advanced functional class. All patients received beta-blockers, and most had a high rate of guideline-directed therapy. At 18 months, the mortality rate was 36.2% and the hospitalisation rate was 42%. The LEVO-D score showed good predictive value for hospitalisation (AUC 0.81), moderate predictive value for clinical response (AUC 0.64), and poor predictive value for mortality (AUC 0.58). A cut-off value of ≥1.0 provided the optimal balance between sensitivity and specificity for identifying responders. CONCLUSIONS: The LEVO-D score showed consistent discriminatory capacity in our cohort despite a high rate of optimal medical therapy and a low rate of edge-to-edge transcatheter repair, thus supporting its utility and encouraging further validation in diverse clinical settings.
No takes yet. Share an insight, caveat, or question.
Manrique-Samer et al. (2026) conducted an observational in advanced heart failure (n=67). LEVO-D score was evaluated on hospitalisation, clinical response, and mortality (AUC 0.81 for hospitalisation). The LEVO-D score demonstrated good predictive value for hospitalisation and moderate predictive value for clinical response in patients with advanced heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: